Loading stock analysis…
Evidence Synthesis
Last synthesized: 23 Aug 2026, 01:38
Narrative updating · score is newerSee how this stock's evidence score moved across recent sessions — unlock Pro for the live chart.
Full momentum history unlocks with Pro or Research.
Evidence Synthesis
MEDPLUS has accelerated its 25.8%, up from 2.94%.
The company's revenue growth has also accelerated, moving from to 21.8% (quarterly cadence). Additionally, MEDPLUS's close price has accelerated, increasing from 656.3 INR to (daily cadence). These positive trends indicate a strong upward momentum in the company's performance.
Source observations behind the synthesis narrative.
| Metric | Value | Trend | |
|---|---|---|---|
| GROSS_MARGIN | 25.8 % | 2.94 | ▲ |
| MARGINAL_OPERATING_LEVERAGE | 2.94 % | 2.91 | ▲ |
| REVENUE_GROWTH_YOY | 21.8 % | -21.8 | ▲ |
| EPS_ACTUAL | 4.62 INR | 4.81 | ▼ |
| EPS_SURPRISE_PERCENT | 0.113 % | 0.061 | ▲ |
| PRICE_CHANGE_PERCENT | 5.066 % | — | - |
| DAILY_VOLUME | 2,87,338 shares | 2,40,581 | ▲ |
| CLOSE_PRICE | 689.55 INR | 656.3 | ▲ |
| NEWS_SENTIMENT_SCORE | 1 score | — | - |
| ANALYST_STRONG_BUY_COUNT | 2 count | 5 | ▼ |
| TARGET_PRICE_PREMIUM | 46.93 % | — | - |